CSIMarket Company Name, Ticker, Competitors, else..


Inhibrx Biosciences Inc   (NASDAQ: INBX)
Other Ticker:  
 

Inhibrx Biosciences Inc

INBX's Fundamental analysis



Inhibrx Biosciences Inc 's sales fell in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 2734

Biotechnology & Pharmaceuticals industry recorded growth of revenues by 13.29 %

Inhibrx Biosciences Inc net loss decreased from $-52 millions, to $-44 millions in III. Quarter 2024,

• More on INBX's Growth


Inhibrx Biosciences Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Inhibrx Biosciences Inc PEG ratio is at -0 Inhibrx Biosciences Inc realized cash reduction of $ -9.12 per share in trailing twelve-month period.
Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
0.11
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 113.65.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.06.


• More on INBX's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ -
 Net Income/Employee (TTM) $ -
 Receivable Turnover (TTM) -
 Tangible Book Value (Per Share $) 11.54

Inhibrx Biosciences Inc
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Inhibrx Biosciences Inc PEG ratio is at -0 Inhibrx Biosciences Inc realized cash outflow of $ -9.12per share in trailing twelve-month period.
Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months.
Company
0.11
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 113.65.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.06.

Inhibrx Biosciences Inc Price to Book Ratio is at 1.1 higher than Industry Avg. of -0, and higher than S&P 500 Avg. of 0.01

• More on INBX's Valuation

•  Market Capitalization (Millions $) 197
•  Shares Outstanding (Millions) 15
•  Employees 89
•  Revenues (TTM) (Millions $) -
•  Net Income (TTM) (Millions $) 1,642
•  Cash Flow (TTM) (Millions $) -141
•  Capital Exp. (TTM) (Millions $) -6
•  Total Debt (Millions $) -
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ -
•  Net Income/Employee(TTM) $ -
•  Receivable Turnover Ratio (TTM) -
•  Tangible Book Value (Per Share $) 11.54

•  Market Capitalization (Millions $) 197
•  Shares Outstanding (Millions) 15
•  Employees 89
•  Revenues (TTM) (Millions $) -
•  Net Income (TTM) (Millions $) 1,642
•  Cash Flow (TTM) (Millions $) -141
•  Capital Exp. (TTM) (Millions $) -6





  Ratio
•   Capital Ratio (MRQ) 4.91
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) 0.24
•  Asset Turnover Ratio (TTM) -
•  Inventory Turnover Ratio (TTM) -





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com